Peptide comparisons
59 pairs people often look up together, side by side: FDA status, the HHS and FDA compounding lists, the kinds of studies each profile cites, and recent official events.
Every row comes from the two published profiles and keeps their citations. A comparison is not a ranking or a recommendation. For a single peptide, see all peptides or the status tracker; for lists, see common questions.
Metabolic and weight
| Comparison | First | Second |
|---|---|---|
| Semaglutide vs Tirzepatide | FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗ | FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗ |
| Tirzepatide vs Retatrutide | FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗ | In clinical trialsIn clinical trials; not FDA-approved↗↗↗ |
| Semaglutide vs Retatrutide | FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗ | In clinical trialsIn clinical trials; not FDA-approved↗↗↗ |
| Liraglutide vs Semaglutide | FDA-approvedFDA-approved as Victoza, Saxenda and generic versions↗↗↗↗ | FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗ |
| Liraglutide vs Tirzepatide | FDA-approvedFDA-approved as Victoza, Saxenda and generic versions↗↗↗↗ | FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗ |
| Dulaglutide vs Semaglutide | FDA-approvedFDA-approved as Trulicity↗↗ | FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗ |
| Dulaglutide vs Tirzepatide | FDA-approvedFDA-approved as Trulicity↗↗ | FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗ |
| Exenatide vs Liraglutide | FDA-approvedFDA-approved as Byetta, Bydureon and generic exenatide↗↗↗↗↗ | FDA-approvedFDA-approved as Victoza, Saxenda and generic versions↗↗↗↗ |
| Cagrilintide vs Semaglutide | In clinical trialsIn clinical trials; not FDA-approved↗↗↗ | FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗ |
| Survodutide vs Retatrutide | In clinical trialsIn clinical trials; not FDA-approved↗↗↗ | In clinical trialsIn clinical trials; not FDA-approved↗↗↗ |
| Survodutide vs Tirzepatide | In clinical trialsIn clinical trials; not FDA-approved↗↗↗ | FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗ |
| Mazdutide vs Tirzepatide | Approval reported abroadChina: approval reported by local government sources↗↗ | FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗ |
| Maridebart cafraglutide vs Tirzepatide | In clinical trialsIn clinical trials; not FDA-approved↗↗↗ | FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗ |
| Amycretin vs Semaglutide | In clinical trialsIn clinical trials; not FDA-approved↗↗ | FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗ |
| Pramlintide vs Cagrilintide | FDA-approvedFDA-approved as Symlin↗↗ | In clinical trialsIn clinical trials; not FDA-approved↗↗↗ |
| Petrelintide vs Cagrilintide | In clinical trialsIn clinical trials; not FDA-approved↗↗↗ | In clinical trialsIn clinical trials; not FDA-approved↗↗↗ |
| AOD-9604 vs Semaglutide | Not FDA-approvedNot FDA-approved; FDA advised against adding it to the compounding list↗↗↗ | FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗ |
| AOD-9604 vs Tesamorelin | Not FDA-approvedNot FDA-approved; FDA advised against adding it to the compounding list↗↗↗ | FDA-approvedFDA-approved as Egrifta for HIV-associated abdominal fat↗↗ |
| Glucagon vs Dasiglucagon | FDA-approvedFDA-approved as Gvoke, Baqsimi and other glucagon products↗↗↗↗ | FDA-approvedFDA-approved as Zegalogue for severe low blood sugar; discontinued↗↗ |
| Orforglipron vs Semaglutide | FDA-approvedFDA-approved as Foundayo for weight reduction in adults↗↗ | FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗ |
| Orforglipron vs Tirzepatide | FDA-approvedFDA-approved as Foundayo for weight reduction in adults↗↗ | FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗ |
| Efpeglenatide vs Semaglutide | In clinical trialsIn clinical trials; not FDA-approved↗↗↗ | FDA-approvedFDA-approved as Ozempic, Rybelsus and Wegovy↗↗↗↗ |
| Albiglutide vs Dulaglutide | FDA-approvedFDA-approved as Tanzeum; discontinued↗ | FDA-approvedFDA-approved as Trulicity↗↗ |
| VK2735 vs Tirzepatide | In clinical trialsIn clinical trials; not FDA-approved↗↗↗ | FDA-approvedFDA-approved as Mounjaro and Zepbound↗↗↗ |
Liver
Hormones
| Comparison | First | Second |
|---|---|---|
| CJC-1295 vs Ipamorelin | Not FDA-approvedUnapproved new drug in cited enforcement record↗ | Not FDA-approvedUnapproved new drug in cited enforcement record↗ |
| Sermorelin vs Tesamorelin | Not FDA-approvedFDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness↗↗ | FDA-approvedFDA-approved as Egrifta for HIV-associated abdominal fat↗↗ |
| Ipamorelin vs Sermorelin | Not FDA-approvedUnapproved new drug in cited enforcement record↗ | Not FDA-approvedFDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness↗↗ |
| CJC-1295 vs Sermorelin | Not FDA-approvedUnapproved new drug in cited enforcement record↗ | Not FDA-approvedFDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness↗↗ |
| CJC-1295 vs Tesamorelin | Not FDA-approvedUnapproved new drug in cited enforcement record↗ | FDA-approvedFDA-approved as Egrifta for HIV-associated abdominal fat↗↗ |
| Ipamorelin vs Tesamorelin | Not FDA-approvedUnapproved new drug in cited enforcement record↗ | FDA-approvedFDA-approved as Egrifta for HIV-associated abdominal fat↗↗ |
| GHRP-2 vs GHRP-6 | Not FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗ | Not FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗ |
| GHRP-2 vs Ipamorelin | Not FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗ | Not FDA-approvedUnapproved new drug in cited enforcement record↗ |
| GHRP-6 vs Ipamorelin | Not FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗ | Not FDA-approvedUnapproved new drug in cited enforcement record↗ |
| GHRP-6 vs Hexarelin | Not FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗ | Not FDA-approvedNo FDA approval reported↗↗ |
| Octreotide vs Lanreotide | FDA-approvedFDA-approved as Sandostatin and other octreotide products↗↗↗↗↗ | FDA-approvedFDA-approved as Somatuline Depot and other lanreotide products↗↗↗↗ |
| Oxytocin vs Vasopressin | FDA-approvedFDA-approved as Pitocin for labor and bleeding after birth↗↗ | FDA-approvedFDA-approved as Vasostrict for vasodilatory shock↗↗ |
| Desmopressin vs Vasopressin | FDA-approvedFDA-approved as DDAVP for diabetes insipidus and bedwetting↗↗ | FDA-approvedFDA-approved as Vasostrict for vasodilatory shock↗↗ |
| MK-677 vs Ipamorelin | Not FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗↗ | Not FDA-approvedUnapproved new drug in cited enforcement record↗ |
| MK-677 vs Sermorelin | Not FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗↗ | Not FDA-approvedFDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness↗↗ |
| MK-677 vs Tesamorelin | Not FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list (category 2)↗↗ | FDA-approvedFDA-approved as Egrifta for HIV-associated abdominal fat↗↗ |
Bone and growth
| Comparison | First | Second |
|---|---|---|
| Teriparatide vs Abaloparatide | FDA-approvedFDA-approved as Forteo and other teriparatide products↗↗↗↗↗↗ | FDA-approvedFDA-approved as Tymlos for osteoporosis↗↗ |
| Mecasermin vs IGF-1 LR3 | FDA-approvedFDA-approved as Increlex for severe primary IGF-1 deficiency in children↗↗ | Not FDA-approvedNo FDA approval reported; studied only in cells and animals↗↗ |
Gut and digestion
| Comparison | First | Second |
|---|---|---|
| BPC-157 vs TB-500 | Not FDA-approvedNot an FDA-approved drug↗ | Not FDA-approvedNot an FDA-approved drug↗ |
| BPC-157 vs KPV | Not FDA-approvedNot an FDA-approved drug↗ | Not FDA-approvedNot an FDA-approved drug↗ |
| BPC-157 vs GHK-Cu | Not FDA-approvedNot an FDA-approved drug↗ | Not FDA-approvedFDA compounding-list review for non-injectable routes↗ |
| Linaclotide vs Plecanatide | FDA-approvedFDA-approved as Linzess↗↗ | FDA-approvedFDA-approved as Trulance↗↗ |
| Teduglutide vs Glepaglutide | FDA-approvedFDA-approved as Gattex for short bowel syndrome↗↗ | In clinical trialsIn clinical trials; not FDA-approved↗↗ |
Brain, nerves and sleep
| Comparison | First | Second |
|---|---|---|
| Epitalon vs MOTS-c | Not FDA-approvedNot an FDA-approved drug↗ | Not FDA-approvedNot an FDA-approved drug↗ |
| Semax vs Selank | Not FDA-approvedNot an FDA-approved drug↗ | Not FDA-approvedNo FDA approval reported; FDA lists safety concerns from a withdrawn compounding nomination↗ |
Skin
| Comparison | First | Second |
|---|---|---|
| Melanotan II vs Bremelanotide | Not FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list↗ | FDA-approvedFDA-approved as Vyleesi for HSDD in premenopausal women↗↗ |
| Melanotan II vs Afamelanotide | Not FDA-approvedNo FDA approval reported; on FDA’s compounding safety-risk list↗ | FDA-approvedFDA-approved as Scenesse for erythropoietic protoporphyria↗↗ |
Sexual and reproductive health
| Comparison | First | Second |
|---|---|---|
| Cetrorelix vs Ganirelix | FDA-approvedFDA-approved as Cetrotide for use in controlled ovarian stimulation↗↗ | FDA-approvedFDA-approved as ganirelix acetate for use in controlled ovarian hyperstimulation↗↗ |
| Gonadorelin vs Leuprolide | FDA-approvedFDA-approved as Factrel and Lutrepulse; discontinued↗↗ | FDA-approvedFDA-approved as Lupron, Eligard, Vobrig and other leuprolide products↗↗↗↗↗↗ |
Tissue repair and wound healing
| Comparison | First | Second |
|---|---|---|
| TB-500 vs Thymosin beta-4 | Not FDA-approvedNot an FDA-approved drug↗ | Not FDA-approvedNo FDA approval reported↗↗ |
Inflammation and immune
Cancer
| Comparison | First | Second |
|---|---|---|
| Leuprolide vs Triptorelin | FDA-approvedFDA-approved as Lupron, Eligard, Vobrig and other leuprolide products↗↗↗↗↗↗ | FDA-approvedFDA-approved as Trelstar for advanced prostate cancer↗↗ |
| Goserelin vs Leuprolide | FDA-approvedFDA-approved as Zoladex for prostate cancer, breast cancer and endometriosis↗↗ | FDA-approvedFDA-approved as Lupron, Eligard, Vobrig and other leuprolide products↗↗↗↗↗↗ |
| Degarelix vs Leuprolide | FDA-approvedFDA-approved as Firmagon for advanced prostate cancer↗↗ | FDA-approvedFDA-approved as Lupron, Eligard, Vobrig and other leuprolide products↗↗↗↗↗↗ |